Puma Biotechnology, Inc.

NASDAQ:PBYI

Biotechnology

Healthcare
$7.22 +2.21%

+$0.16 today

Market cap
$373.26M
Beta
1.21
P/E (TTM)
15.4
EPS (TTM)
$0.48
52W Low $3.03High $7.90

Volume 0.45M

Average 0.26M

PBYI Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Puma Biotechnology, Inc.NASDAQ: PBYI

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow declines year over year

Q1 FY2026 financing cash flow of $11.3M (cash outflow) fell 0.3% year over year, in line with the -0.0% change in trailing-twelve-month financing cash flow. Sequentially, it fell 0.3% from the prior quarter.

Context

  • Financing cash flow amounted to 19.8% of revenue in FY2025, up 5.1 pp from a year earlier.
  • Financing cash flow increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -0.3% toward the trailing-twelve-month pace of -0.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$11.3M-0.3% QoQ
Last fiscal yearDec 2025
-$45.2M+33.5% YoY
LTMMar 2026
-$45.17M-0.0% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.3%——
1 year+33.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
(45.2M) USD
Year-over-year change
-33.5%

Financing Cash Flow vs competitors

How PBYI compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -0.0% is the 7th highest of 10, against a peer median of +114.9%.
  • Financing cash flow amounts to 19.9% of revenue for PBYI, versus a peer median of 279.2%.
PBYI Competitors
Financing Cash Flow for PBYI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TNGXTango Therapeutics, Inc.LTM Sep 2026$974.19M USD+23701.4%+416.5%—
NBPNovaBridge BiosciencesLTM Sep 2025CN¥433.38M CNY—+10.9%—
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$306.39M USD+17210.3%+114.1%—
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$251.18M USD+3158.7%+6.2%—
VSTMVerastem, Inc.LTM Mar 2026$224.57M USD+85.0%+72.0%452.9%
NUVBNuvation Bio Inc.LTM Jun 2026$179.14M USD-6.5%+434.4%105.4%
MGNXMacroGenics, Inc.LTM Mar 2026$69.59M USD+16083.5%+247.3%44.3%
PBYIPuma Biotechnology, Inc.LTM Mar 2026$45.17M USD-0.0%—19.9%
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$23.71M CAD+114.9%+16.7%—
CRDFCardiff Oncology, Inc.LTM Mar 2026$2.68M USD-95.0%+225.3%511.0%
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026$363K USD-101.7%——
Peer median (excluding PBYI) —+114.9%+114.1%279.2%

Competitors are the stored peer set for PBYI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(29.13M)2K21.59M30.28M31.11M
Depreciation & Amortization11.31M9.84M11.52M11.52M10.94M
Deferred Income Tax000(7.08M)3.25M
Stock-Based Compensation32.63M11.83M10.25M8.25M6.94M
Change in Working Capital(1.31M)(44.5M)(17.85M)(3.54M)(10.08M)
Accounts Receivables(5.98M)(7.82M)(8.37M)16.35M(21.28M)
Inventory(3.66M)2.58M(2.55M)(1.64M)3.21M
Accounts Payables(902K)(4.73M)449K(1.38M)(453K)
Other Working Capital9.23M(34.52M)(7.38M)(16.86M)8.45M
Other Non-Cash Items7.15M7M1.51M(519K)(358K)
Operating Cash Flow20.65M(15.83M)27.01M38.92M41.8M
Capital Expenditures0(7M)(12.64M)(56K)(71K)
Acquisitions (Net)00000
Purchases of Investments(38.07M)(4.84M)(23.81M)(76.23M)(108.14M)
Sales of Investments27.19M18.94M17.33M55.85M72.02M
Other Investing Activities00(12.5M)00
Investing Cash Flow(10.88M)7.1M(19.13M)(20.44M)(36.19M)
Debt Repayment(1.5M)00(33.33M)(44.44M)
Common Stock Issued012.5M0150K130K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(30.43M)(277K)0(666K)(888K)
Financing Cash Flow(31.93M)12.22M0(33.85M)(45.2M)
Effect of Forex Changes00000
Net Change in Cash(22.16M)3.5M7.88M(15.37M)(39.58M)
Free Cash Flow20.65M(22.83M)14.37M38.86M41.73M

Puma Biotechnology, Inc.

NASDAQ:PBYI

Intrinsic Alpha fair value

Locked

Current Price

$7.22

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.